67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma

NCT04023331 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

21

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Neuroblastoma
Relapsed Neuroblastoma
Refractory Neuroblastoma

Interventions

DRUG: 67Cu-SARTATE
DRUG: 64Cu-SARTATE

Sponsor

Clarity Pharmaceuticals Ltd